Fidelity Biosciences News - Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies.

Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention

	Printable Version
	Send to a Colleague

Watertown, MA, April 29, 2010 - Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resistant infections, taking place at the 2010 BIO International Convention in Chicago.

On Wednesday, May 5 at 8:00 a.m., Joyce Sutcliffe, Ph.D., senior vice president, Biology at Tetraphase Pharmaceuticals, will be making a presentation during a Session entitled "Where Are the Drugs to Stop Bad Bugs?" in Room S401-AB at the McCormick Place convention center.

Dr. Sutcliffe will be among speakers who will discuss new drugs in development to combat drug-resistant infections, many of which are fatal and continue to grow in number and severity. The session will focus on novel approaches to creating important new and powerful antibacterial agents, including Tetraphase’s development pipeline, to address the growing unmet medical need, of serious infections caused by drug-resistant gram-negative bacterial pathogens, where there are few existing treatment options.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offering key networking and partnering opportunities, and provides insights and inspiration on the major trends in the industry today. For more information on BIO 2010 visit http://convention.bio.org.

About Tetraphase Pharmaceuticals Inc.
Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories. Tetraphase has an emerging antibiotic franchise of novel antibiotics with the potential for IV/oral broad spectrum and more treatment of drug-resistant infections with unmet medical needs.

Contact
Adriana Jenkins
The Yates Network
(617) 744-1713